Author

Xinyan Wu

Mayo ClinicPrimary ORCID profile (0000-0002-7745-1614 · 1 paper)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Xinyan WuiD1 paper · Mayo Clinic

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

Ann L. ObergiD· 1 shared Anya Zhao· 1 shared Jamie Nadine Bakkum-GameziD· 1 shared Jamison L. VanBlaricom· 1 shared Jeremy ChieniD· 1 shared John Weroha· 1 shared Julie K. StaubiD· 1 shared Ling Jin· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Ann L. ObergORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Drug-induced nuclear cathepsin L (nCTSL) defines a targetable DNA damage response axis and PARP inhibitor sensitivity in ovarian cancer

Prabhu Thirusangu, Ling Jin, Shruti Rao, Upasana Ray, Anya Zhao, Julie K. Staub, Xinyan Wu, Xiaonan Hou, Jamison L. VanBlaricom, Syed Mohammed Musheer Aalam, Sun-Hee Lee, Ann L. Oberg, Nagarajan Kannan, John Weroha, Jeremy Chien, , Viji Shridhar

This study identifies nuclear cathepsin L (nCTSL) as a biomarker for PARP inhibitor sensitivity in ovarian cancer and shows that combining clofarabine with PARP inhibitors enhances therapeutic response.

Cell Communication and Signaling · Aug 28, 2026Peer-reviewedCancer Biology